Teva’s Biaxin XL Generic Barred From Launch Pending May 26 Hearing
This article was originally published in The Pink Sheet Daily
Executive Summary
A temporary restraining order prevents Teva from launching its extended-release generic upon the May 23 expiration of the clarithromycin compound patent. Abbott already has gotten a jump on potential generic versions of immediate-release Biaxin with an “authorized” generic sold through Dava.
You may also be interested in...
Teva's Biaxin XL Generic Would Irreparably Harm Abbott, Court Rules
Teva is preliminarily enjoined from launching extended-release clarithromycin pending a ruling on the merits of patent infringement claims. A Chicago federal judge preliminarily rules that only one of three Abbott patents at issue is valid. Teva expects to file an expedited appeal to the Federal Circuit.
Teva's Biaxin XL Generic Would Irreparably Harm Abbott, Court Rules
Teva is preliminarily enjoined from launching extended-release clarithromycin pending a ruling on the merits of patent infringement claims. A Chicago federal judge preliminarily rules that only one of three Abbott patents at issue is valid. Teva expects to file an expedited appeal to the Federal Circuit.
Temporary Restraining Order Barring Teva's Biaxin XL Generic Extended
The TRO, which was originally was slated to expire May 30, has been extended pending a ruling by a Chicago federal judge on Abbott's request for a preliminary injunction. Abbott expects a ruling from the court either on June 3 or early in the week of June 6.